Dr. Laurence Albiges outlines how belzutifan is reshaping kidney cancer treatment across disease stages. In the adjuvant setting, adding belzutifan...

Dr. Elizabeth Plimack reviews how KEYNOTE-B61 supports lenvatinib plus pembrolizumab as a strong frontline option in non–clear cell RCC, particularly...

Dr. David Braun discusses HPK1 inhibition as a novel immunotherapy approach targeting an intracellular immune “brake” in kidney cancer. Early...

Dr. Sophia Cameron discusses how radiation therapy fits into evolving GU cancer care, particularly for symptomatic lesions and oligometastatic prostate...

Dr. Scott Tagawa reviews the PSMAddition trial, showing that adding lutetium PSMA-617 to ADT and ARPI improves progression-free outcomes but...

Dr. Matt Galsky highlights how data from CREST and KEYNOTE trials support expanding immunotherapy use in bladder cancer, particularly in...

Trodelvy (sacituzumab govitecan-hziy) is a Trop-2–targeted antibody–drug conjugate recently recommended by the NCCN as a Category 1 first-line therapy for...

Recent advances have reshaped the management of HR-positive, HER2-negative metastatic breast cancer, with CDK4/6 inhibitors, genomically driven targeted therapies, and...

In the phase 3 PATINA trial, adding the CDK4/6 inhibitor palbociclib to maintenance HER2-targeted and endocrine therapy significantly prolonged progression-free...

The FDA has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) plus pertuzumab for first-line treatment of unresectable or metastatic HER2-positive breast cancer....

At SABCS 2025, new data evaluated whether multimodal artificial intelligence (MMAI) can be trusted to support clinical decision-making in early-stage...

Key data from SABCS 2025 highlight how endocrine-based, biology-driven strategies continue to reshape the management of ER-positive, HER2-negative breast cancer....

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zongertinib (Hernexeos) for adults with unresectable or metastatic...

Nuvalent announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for zidesamtinib for...

Recent studies, including FLAURA2 and MARIPOSA, show that combination therapies are improving survival for patients with EGFR-mutated NSCLC, though higher...

Final results from the phase III FLAURA2 trial demonstrate that adding platinum–pemetrexed chemotherapy to first-line osimertinib significantly improves overall survival...

The FDA has approved subcutaneous amivantamab (Rybrevant Faspro) for adult patients with advanced or metastatic EGFR-mutated NSCLC. In the Phase...

The FDA has granted full approval to Tarlatamab-dlle (Imdelltra) for patients with extensive-stage small-cell lung cancer progressing after platinum therapy....

The phase III BREAKWATER trial evaluated early integration of targeted therapy with encorafenib plus cetuximab in combination with chemotherapy for...

The United States Food and Drug Administration (FDA) has approved Tumor Treating Fields (TTFields) therapy delivered via the Optune Lua...

HERIZON-GEA-01 is a pivotal phase III trial evaluating zanidatamab-based regimens, with or without the PD-1 inhibitor tislelizumab, compared with trastuzumab...

The phase III COMMIT trial demonstrates that intensifying first-line immunotherapy with chemotherapy and antiangiogenic therapy can substantially improve outcomes for...

Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) represent a biologically distinct subgroup with historically poor outcomes and limited first-line,...

The FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with FLOT chemotherapy as the first and only perioperative immunotherapy for...

As oncology enters 2026, the field is shifting from reactive treatment toward anticipatory, precision-driven care. In this article, experts highlight...

ASCENT-03 trial shows Trodelvy plus pembrolizumab significantly improved PFS vs chemo plus pembrolizumab in first-line mTNBC patients.

FDA approves lurbinectedin plus atezolizumab for ES-SCLC maintenance, extending OS to 13.2 months vs 10.6 months with atezolizumab alone (HR...

FDA grants Priority Review for Enhertu plus pertuzumab in first-line HER2+ metastatic breast cancer, with decision expected April 2025.

FDA approves gemcitabine intravesical system for BCG-unresponsive bladder cancer, showing 82% complete response rate in SunRISe-1 trial.

Modeyso, the first treatment option for this ultra-rare and aggressive brain tumor, is commercially available in the US.